

Appl. No. : 10/501,666
Filed : July 16, 2004

REMARKS

This response to the Notice to Comply brings the patent application into compliance with the Sequence Listing Disclosure requirement of the USPTO. The previously submitted sequence listing has been revised as suggested by STIC. That is, in cases where "n" was identified as a non-nucleotide compound, now the closest nucleotide is indicated as labelled in the <220>-<223> section. In addition, extraneous characters at the end of the sequence listing have been removed.

Enclosed herewith are: (1) a paper copy of the Replacement Sequence Listing, and (2) a computer readable version of the Replacement Sequence Listing (2 copies). The Response to Notice to Comply directs entry of the paper copy of the Sequence Listing into the application. In view of the foregoing, the application is believed to fully comply with the Sequence Listing Disclosure requirements. A copy of the Notice to Comply is also included.

VERIFICATION UNDER 37 C.F.R. § 1.821 (f) & (g)

All of the sequences in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. § 1.821 (g), no new matter is being added herewith. As required under 37 C.F.R. § 1.821 (f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.

Conclusion

No fees are believed due; however, should any fees be required, please charge them to Deposit Account No. 11-1410. Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Dec. 20, 2004

By: Che S. Chereskin

Che Swyden Chereskin
Registration No. 41,466
Agent of Record
Customer No. 20,995